Literature DB >> 28724787

Disrupted apical exocytosis of cargo vesicles causes enteropathy in FHL5 patients with Munc18-2 mutations.

Georg F Vogel1,2, Jorik M van Rijn3, Iris M Krainer1,2, Andreas R Janecke1, Carsten Posovszky4, Marta Cohen5, Claire Searle6, Prevost Jantchou7, Johanna C Escher8, Natalie Patey6, Ernest Cutz9, Thomas Müller1, Sabine Middendorp3, Michael W Hess10, Lukas A Huber2.   

Abstract

Familial hemophagocytic lymphohistiocytosis 5 (FHL5) is an autosomal recessive disease caused by mutations in STXBP2, coding for Munc18-2, which is required for SNARE-mediated membrane fusion. FHL5 causes hematologic and gastrointestinal symptoms characterized by chronic enteropathy that is reminiscent of microvillus inclusion disease (MVID). However, the molecular pathophysiology of FHL5-associated diarrhea is poorly understood. Five FHL5 patients, including four previously unreported patients, were studied. Morphology of duodenal sections was analyzed by electron and fluorescence microscopy. Small intestinal enterocytes and organoid-derived monolayers displayed the subcellular characteristics of MVID. For the analyses of Munc18-2-dependent SNARE-protein interactions, a Munc18-2 CaCo2-KO model cell line was generated by applying CRISPR/Cas9 technology. Munc18-2 is required for Slp4a/Stx3 interaction in fusion of cargo vesicles with the apical plasma membrane. Cargo trafficking was investigated in patient biopsies, patient-derived organoids, and the genome-edited model cell line. Loss of Munc18-2 selectively disrupts trafficking of certain apical brush-border proteins (NHE3 and GLUT5), while transport of DPPIV remained unaffected. Here, we describe the molecular mechanism how the loss of function of Munc18-2 leads to cargo-selective mislocalization of brush-border components and a subapical accumulation of cargo vesicles, as it is known from the loss of polarity phenotype in MVID.

Entities:  

Keywords:  Cell Biology; Epithelial transport of ions and water; Gastroenterology; Molecular genetics; Protein traffic

Year:  2017        PMID: 28724787      PMCID: PMC5518552          DOI: 10.1172/jci.insight.94564

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  49 in total

1.  Rapamycin Inhibition of mTOR Reduces Levels of the Na+/H+ Exchanger 3 in Intestines of Mice and Humans, Leading to Diarrhea.

Authors:  Jun Yang; Xiaofeng Zhao; Archana Patel; Rachana Potru; Sadra Azizi-Ghannad; Michael Dolinger; James Cao; Catherine Bartholomew; Joseph Mazurkiewicz; David Conti; David Jones; Yunfei Huang; Xinjun Cindy Zhu
Journal:  Gastroenterology       Date:  2015-03-30       Impact factor: 22.682

2.  Microvillous inclusion disease: ultrastructural variability.

Authors:  Theodore C Iancu; Muhammad Mahajnah; Irena Manov; Ron Shaoul
Journal:  Ultrastruct Pathol       Date:  2007 May-Jun       Impact factor: 1.094

3.  Spectrum of clinical presentations in familial hemophagocytic lymphohistiocytosis type 5 patients with mutations in STXBP2.

Authors:  Marie Meeths; Miriam Entesarian; Waleed Al-Herz; Samuel C C Chiang; Stephanie M Wood; Wafa Al-Ateeqi; Francisco Almazan; Jaap J Boelens; Henrik Hasle; Marianne Ifversen; Bendik Lund; J Merlijn van den Berg; Britt Gustafsson; Hans Hjelmqvist; Magnus Nordenskjöld; Yenan T Bryceson; Jan-Inge Henter
Journal:  Blood       Date:  2010-06-17       Impact factor: 22.113

4.  Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11.

Authors:  Udo zur Stadt; Susanne Schmidt; Brigitte Kasper; Karin Beutel; A Sarper Diler; Jan-Inge Henter; Hartmut Kabisch; Reinhard Schneppenheim; Peter Nürnberg; Gritta Janka; Hans Christian Hennies
Journal:  Hum Mol Genet       Date:  2005-02-09       Impact factor: 6.150

5.  Loss of syntaxin 3 causes variant microvillus inclusion disease.

Authors:  Caroline L Wiegerinck; Andreas R Janecke; Kerstin Schneeberger; Georg F Vogel; Désirée Y van Haaften-Visser; Johanna C Escher; Rüdiger Adam; Cornelia E Thöni; Kristian Pfaller; Alexander J Jordan; Cleo-Aron Weis; Isaac J Nijman; Glen R Monroe; Peter M van Hasselt; Ernest Cutz; Judith Klumperman; Hans Clevers; Edward E S Nieuwenhuis; Roderick H J Houwen; Gijs van Haaften; Michael W Hess; Lukas A Huber; Janneke M Stapelbroek; Thomas Müller; Sabine Middendorp
Journal:  Gastroenterology       Date:  2014-04-12       Impact factor: 22.682

6.  Myosin Vb uncoupling from RAB8A and RAB11A elicits microvillus inclusion disease.

Authors:  Byron C Knowles; Joseph T Roland; Moorthy Krishnan; Matthew J Tyska; Lynne A Lapierre; Paul S Dickman; James R Goldenring; Mitchell D Shub
Journal:  J Clin Invest       Date:  2014-06-02       Impact factor: 14.808

7.  Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients.

Authors:  Nizar Mahlaoui; Marie Ouachée-Chardin; Geneviève de Saint Basile; Bénédicte Neven; Capucine Picard; Stéphane Blanche; Alain Fischer
Journal:  Pediatrics       Date:  2007-08-14       Impact factor: 7.124

8.  MYO5B mutations cause microvillus inclusion disease and disrupt epithelial cell polarity.

Authors:  Thomas Müller; Michael W Hess; Natalia Schiefermeier; Kristian Pfaller; Hannes L Ebner; Peter Heinz-Erian; Hannes Ponstingl; Joachim Partsch; Barbara Röllinghoff; Henrik Köhler; Thomas Berger; Henning Lenhartz; Barbara Schlenck; Roderick J Houwen; Christopher J Taylor; Heinz Zoller; Silvia Lechner; Olivier Goulet; Gerd Utermann; Frank M Ruemmele; Lukas A Huber; Andreas R Janecke
Journal:  Nat Genet       Date:  2008-08-24       Impact factor: 38.330

9.  Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11.

Authors:  Udo zur Stadt; Jan Rohr; Wenke Seifert; Florian Koch; Samantha Grieve; Julia Pagel; Julia Strauss; Brigitte Kasper; Gudrun Nürnberg; Christian Becker; Andrea Maul-Pavicic; Karin Beutel; Gritta Janka; Gillian Griffiths; Stephan Ehl; Hans Christian Hennies
Journal:  Am J Hum Genet       Date:  2009-10       Impact factor: 11.025

10.  A technique for ultracryotomy of cell suspensions and tissues.

Authors:  K T Tokuyasu
Journal:  J Cell Biol       Date:  1973-05       Impact factor: 10.539

View more
  18 in total

1.  The Hippo Pathway Is Essential for Maintenance of Apicobasal Polarity in the Growing Intestine of Caenorhabditis elegans.

Authors:  Hanee Lee; Junsu Kang; Soungyub Ahn; Junho Lee
Journal:  Genetics       Date:  2019-07-29       Impact factor: 4.562

2.  Variants in STXBP3 are Associated with Very Early Onset Inflammatory Bowel Disease, Bilateral Sensorineural Hearing Loss and Immune Dysregulation.

Authors:  Jodie Ouahed; Judith R Kelsen; Waldo A Spessott; Kameron Kooshesh; Maria L Sanmillan; Noor Dawany; Kathleen E Sullivan; Kathryn E Hamilton; Voytek Slowik; Sergey Nejentsev; João Farela Neves; Helena Flores; Wendy K Chung; Ashley Wilson; Kwame Anyane-Yeboa; Karen Wou; Preti Jain; Michael Field; Sophia Tollefson; Maiah H Dent; Dalin Li; Takeo Naito; Dermot P B McGovern; Andrew C Kwong; Faith Taliaferro; Jose Ordovas-Montanes; Bruce H Horwitz; Daniel Kotlarz; Christoph Klein; Jonathan Evans; Jill Dorsey; Neil Warner; Abdul Elkadri; Aleixo M Muise; Jeffrey Goldsmith; Benjamin Thompson; Karin R Engelhardt; Andrew J Cant; Sophie Hambleton; Andrew Barclay; Agnes Toth-Petroczy; Dana Vuzman; Nikkola Carmichael; Corneliu Bodea; Christopher A Cassa; Marcella Devoto; Richard L Maas; Edward M Behrens; Claudio G Giraudo; Scott B Snapper
Journal:  J Crohns Colitis       Date:  2021-11-08       Impact factor: 9.071

3.  Advanced Microscopy for Liver and Gut Ultrastructural Pathology in Patients with MVID and PFIC Caused by MYO5B Mutations.

Authors:  Michael W Hess; Iris M Krainer; Przemyslaw A Filipek; Barbara Witting; Karin Gutleben; Ilja Vietor; Heinz Zoller; Denise Aldrian; Ekkehard Sturm; James R Goldenring; Andreas R Janecke; Thomas Müller; Lukas A Huber; Georg F Vogel
Journal:  J Clin Med       Date:  2021-04-28       Impact factor: 4.964

Review 4.  Intestinal epithelial cell polarity defects in disease: lessons from microvillus inclusion disease.

Authors:  Kerstin Schneeberger; Sabrina Roth; Edward E S Nieuwenhuis; Sabine Middendorp
Journal:  Dis Model Mech       Date:  2018-02-13       Impact factor: 5.758

Review 5.  MYO5B, STX3, and STXBP2 mutations reveal a common disease mechanism that unifies a subset of congenital diarrheal disorders: A mutation update.

Authors:  Herschel S Dhekne; Olena Pylypenko; Arend W Overeem; Malik Zibouche; Rosaria J Ferreira; K Joeri van der Velde; Edmond H H M Rings; Carsten Posovszky; Peter van der Sluijs; Morris A Swertz; Anne Houdusse; Sven C D van IJzendoorn
Journal:  Hum Mutat       Date:  2018-01-17       Impact factor: 4.878

6.  Type 5 Familial Hemophagocytic Lymphohistiocytosis in a Seven-year-old Girl Post Second Bone Marrow Transplantation with Failure to Thrive: STXBP2 Novel Mutation.

Authors:  Abdullah Baothman; Hani Almalki; Khalid Abumelha; Abobaker Alshegifi; Abdulrahman Baashar
Journal:  Cureus       Date:  2019-11-27

Review 7.  Haematopoietic Stem Cell Transplantation for Primary Haemophagocytic Lymphohistiocytosis.

Authors:  Kai Lehmberg; Despina Moshous; Claire Booth
Journal:  Front Pediatr       Date:  2019-10-25       Impact factor: 3.418

8.  Effects of undigested protein-rich ingredients on polarised small intestinal organoid monolayers.

Authors:  Soumya K Kar; Bart van der Hee; Linda M P Loonen; Nico Taverne; Johanna J Taverne-Thiele; Dirkjan Schokker; Mari A Smits; Alfons J M Jansman; Jerry M Wells
Journal:  J Anim Sci Biotechnol       Date:  2020-05-18

9.  Dynamic Formation of Microvillus Inclusions During Enterocyte Differentiation in Munc18-2-Deficient Intestinal Organoids.

Authors:  Mohammed H Mosa; Ophélie Nicolle; Sophia Maschalidi; Fernando E Sepulveda; Aurelien Bidaud-Meynard; Constantin Menche; Birgitta E Michels; Grégoire Michaux; Geneviève de Saint Basile; Henner F Farin
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2018-08-14

10.  Modeling Microvillus Inclusion Formation In Vitro.

Authors:  Amy C Engevik; James R Goldenring
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2018-09-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.